Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Analyst Comment

OptiCept’s capital raise preliminary outcome at 70% of maximum gross proceeds

By Lucas MattssonAnalyst
OptiCept Technologies

OptiCept has announced the preliminary outcome of their rights issue, which indicates that subscriptions by exercise of subscription rights and subscription applications without subscription rights amount to a total of ~59% of the Rights Issue. Thus, the preliminary outcome indicates that an additional approximately ~11% will be subscribed for by guarantors. In total, the rights issue is therefore expected to reach 70% of the maximum subscription, or 56.4 MSEK before expenses. While we had anticipated the rights issue to be fully subscribed, the fact that the stock price has occasionally traded slightly below the subscription price makes this outcome less surprising.

In practical terms, this means the company retains most of the additional cash runway it aimed to secure with the raise, resulting in relatively minor adjustments to our valuation, which had assumed 100% subscription. As a result, we are not making any immediate changes to our valuation or recommendation.

Login required

This content is only available for logged in users

Create account

OptiCept Technologies

5.1SEK26.11.2024 klo 19.00

OptiCept Technologies is a provider of the food and plant industry with technological solutions that are used to increase the sustainability of various raw materials. The company works with biological processes that provide increased extraction from the raw material, extended shelf life reduced waste, and retained taste, aroma, color, the nutritional content of the end product. The company has a patented technology within PEF (pulsed electric field) and VI (Vacuum Infusion). The company sells its products on a global level and is headquartered in Lund.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.